阿瑞匹坦胶囊说明书

Aprepitant capsules (trade name: Yimei) are the world's first approved NK-1 receptor antagonist antiemetics and the first pitant drug to be marketed in China. It is characterized by crossing the blood-brain barrier and occupying NK-1 receptors in the brain with high selectivity and high affinity, thereby inhibiting the root cause of CINV at the central level. It is a drug used to prevent acute and delayed nausea and vomiting during initial and repeated treatment with highly emetogenic anti-tumor chemotherapy. At present, the capsule has been registered, approved and marketed in more than 90 countries around the world. It has been used in more than 10 million chemotherapy courses worldwide, helping cancer patients relieve nausea and vomiting caused by chemotherapy and improving the quality of life of cancer patients.

Aprepitant was approved for marketing by the US FDA in March 2003 under the trade name Emend. In March 2014, aprepitant was approved for marketing in China, and its products are now available in more than 90 countries and regions around the world. In 2018, global sales of aprepitant were US$522 million. Aprepitant is developed and produced by Merck in the United States. Merck was founded in 1891. The company is headquartered in Kenilworth, New Jersey, and has approximately 69,000 employees worldwide. In 2020, Merck's annual revenue was US$48 billion and its R&D investment exceeded US$13.5 billion.

As a first-line drug and recommended drug for preventing nausea and vomiting caused by highly emetogenic anti-tumor chemotherapy, aprepitant has been unanimously recommended by authoritative European and American guidelines such as the National Comprehensive Cancer Network Clinical Application Guidelines (NCCN). Cancer has become the second leading cause of death in my country, and nausea and vomiting are often associated with many patients receiving chemotherapy. According to research, more than 75% of chemotherapy drugs can cause nausea and vomiting. The pain caused by chemotherapy often makes patients hesitate to continue treatment. Some even lose confidence in life and give up the opportunity for treatment. Aprepitant can effectively prevent vomiting, and its antiemetic regimen combined with 5-HT3 receptor antagonists and glucocorticoids has also been recommended by international authoritative guidelines.

According to the package insert, aprepitant capsules are administered as a three-day intervention and include a course of treatment with a corticosteroid and a 5-HT3 antagonist. The recommended dosage of capsules is 125 mg taken orally one hour before chemotherapy on the first day, and 80 mg once daily in the morning on the second and third days.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.